Korean Gliptins Loom Amid Signs Of Shifts In India
This article was originally published in PharmAsia News
A clutch of new dipeptidyl peptidase-4 (DPP-4) inhibitors including LG Life Sciences Ltd's gemigliptin and Dong-A ST Co. Ltd 's evogliptin have either just hit the Indian market or are on the horizon, amid what some industry watchers say are early signs of a volume shake-up in the highly competitive gliptins market.
You may also be interested in...
Is there a new strategic Asian pharma partnership in the works? Early days perhaps but worth keeping an eye on the India-South Korea deal street.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.